Clinical Trial Update: A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy [Phase 3]

View source ↗

Summary

A Phase 3 study of IBI311 in steroid-resistant thyroid-associated ophthalmopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid-associated Ophthalmopathy

Drugs mentioned

• IBI311

Snippet

Sponsor: Peking University People's Hospital | Conditions: Thyroid Associated Ophthalmopathy | Phase 3 | Status: COMPLETED